Business
-
Elan Corporation has announced that it will pay Theravance $1 billion for a 21% participation interest in future royalty payments from sales of Breo (Relvar) Ellipta, Anoro Ellipta, MABA ‘081 bifunctional muscarinic antagonist-beta2 agonist monotherapy,… Read more . . .
-
Vectura has announced that it has partnered with Chinese pharmaceutical company Tianjin KingYork Group and Hong Kong private equity investor Zendex Bio Strategy to create Tianjin Kinnovata Pharmaceutical Company Limited (“Kinnovata”). The new company will… Read more . . .
-
Alexza Pharmaceuticals and Teva Pharmaceuticals USA have announced that Teva will market Adasuve loxapine inhalation powder for the treatment of agitation associated with schizophrenia or bipolar I disorder in the US. The FDA approved Adasuve… Read more . . .
-
Contract research organization MedPharm has announced the opening of a new GLP laboratory at its Guildford, UK headquarters. According to the company, “The additional space will provide further capacity for MedPharm’s proprietary in vitro/ex vivo… Read more . . .
-
The 19 member companies of the Medicon Valley Inhalation Consortium (MVIC) have announced the creation of a single company called MVIC AB in order to simplify customer relationships with the organization. Orest Lastow of Zenit… Read more . . .
-
Israeli/American biotech company Andain Inc. says that it has developed an “innovative lipid-based drug delivery nano-particles capable of carrying hydrophilic and hydrophobic drugs to a targeted human organ with timely drug release capabilities” and announced… Read more . . .
-
The board of directors of Theravance, Inc. has decided to split the organization into two separate companies by late 2013 or early 2014 in a move “designed to unlock potential value, facilitate return of capital… Read more . . .
-
GW Pharmaceuticals has announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance in response to its patent application for a metered dose spray device for sublingual delivery of… Read more . . .
-
Galapagos subsidiary Argenta has signed an agreement with Boehringer Ingelheim to provide respiratory drug discovery services for “an undisclosed target within Boehringer Ingelheim’s respiratory disease portfolio,” the company said. On its website, Argenta says that… Read more . . .
-
Besins Healthcare will license the Muco (μco) intranasal system from Shin Nippon Biomedical Laboratories (SNBL) for delivery of its BHR-310 progesterone powder, which it is developing for the treatment of mild traumatic brain injury (TBI).… Read more . . .

Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here


